1.

Flowchart of mechanisms for GPs’ everyday clinical decision-making when encountering psychosocial problems in children and youth 1,2 .

1.

Characteristics of GPs–online survey (n = 15) and interviews (n = 14), N = 29.

1.

S1 Fig -

2.

S1 Fig -

3.

S1 Fig -

4.

S1 Fig -

5.

S1 Fig -

6.

S1 Fig -

7.

S1 Fig -

1.

S3 Fig -

2.

S3 Fig -

3.

S3 Fig -

4.

S3 Fig -

5.

S3 Fig -

6.

S3 Fig -

7.

S3 Fig -

1.

S5 Fig -

2.

S5 Fig -

3.

S5 Fig -

1.

S6 Fig -

2.

S6 Fig -

3.

S6 Fig -

1.

CBP per cumulative year for daratumumab and pembrolizumab per vial.

2.

CBP per cumulative year for daratumumab and pembrolizumab per vial.

3.

CBP per cumulative year for daratumumab and pembrolizumab per vial.

1.

CBP per cumulative indication for daratumumab and pembrolizumab per vial.

2.

CBP per cumulative indication for daratumumab and pembrolizumab per vial.

3.

CBP per cumulative indication for daratumumab and pembrolizumab per vial.

1.

Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

2.

Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

3.

Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

1.

Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

2.

Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

3.

Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.